Denmark · Delayed Price · Currency is DKK Embla Medical Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 15% revenue growth (4% organic), stable margins despite tariffs and FX, and 21% bottom-line growth. Guidance for 5%-8% organic growth and 20%-22% EBITDA margin is reiterated, with segment strength in Prosthetics and neuro-orthotics and recovery expected in Patient Care.
-
Q1 2026 saw 15% reported sales growth and 21% net profit growth, with strong Prosthetics & Neuro Orthotics performance and margin pressure from FX and tariffs. Full-year guidance of 5%-8% organic sales growth and 20%-22% EBITDA margin is reiterated.
-
A global leader in mobility solutions is driving growth through innovation, acquisitions, and expanding access to advanced prosthetics and neuro-orthotics. Key growth comes from functional trade-up, recurring sales, and new market penetration, while challenges include reimbursement, tariffs, and geopolitical risks.
Fiscal Year 2025
-
Solid organic and acquisition-driven growth was achieved, with strong cash flow and resilient margins despite tariffs and FX headwinds. Guidance for 2026 anticipates 5%-8% organic growth and 20%-22% EBITDA margin, supported by efficiency gains and new product launches.
-
Solid organic sales growth and profitability were achieved in 2025, driven by strong performance in prosthetics and neuroorthotics, with robust cash flow and margin resilience despite FX and tariff headwinds. 2026 guidance targets 5%-8% organic growth and 20%-22% EBITDA margin.
-
Q3 2025 saw 7% organic and 11% reported sales growth, led by double-digit gains in prosthetics and neuroorthotics, while patient care and bracing/supports lagged. EBITDA margin held at 22%, and full-year guidance for 5%-6% organic growth and 20%-21% EBITDA margin was reiterated.
-
Q3 2025 saw 7% organic sales growth, led by double-digit gains in prosthetics and new orthotics, with EBITDA margin at 22%. Guidance for 5%-6% organic growth and 20%-21% EBITDA margin is reiterated, while tariffs and internal changes impact patient care and bracing segments.
-
Q2 saw 7% revenue growth (5% organic) and a 21% EBITDA margin, with guidance narrowed to 5%-6% organic growth for the year. Strategic moves included the Streifeneder investment and a new U.S. reimbursement code for FIOR & GENTZ, while tariffs and U.S. healthcare changes pose ongoing risks.
-
Q2 saw 7% sales growth and a 21% H1 EBITDA margin, led by Prosthetics and Neuro orthotics, with EMEA outperforming and Americas expected to accelerate in H2. Guidance narrowed to 5–6% organic growth, and a strategic acquisition is pending approval.
-
Navii, a new microprocessor knee, offers premium waterproofing and personalization at a standard price, targeting expanded user segments and differentiating from competitors. User trials show high satisfaction, and the market is expected to grow significantly, driven by expanded reimbursement and innovation.
-
Q1 saw 4% organic sales growth and a higher EBITDA margin, with strong EMEA and APAC performance offset by a slow start in the Americas. Guidance for 5%-8% organic growth and 19-20% EBITDA margin is maintained, but US market recovery is key to meeting targets.
-
Q1 2025 saw 4% organic sales growth to $203M, with EBITDA margin up to 18% and net profit rising 45% year-over-year. EMEA and APAC regions drove growth, while the Americas lagged due to lower patient volumes and reimbursement delays. Full-year guidance for 5%-8% organic growth and 20%-21% EBITDA margin is maintained.
Fiscal Year 2024
-
Achieved solid organic growth and margin expansion in 2024, driven by new product launches, a key acquisition, and expanded U.S. reimbursement. 2025 guidance targets 5%-8% organic growth and higher margins, with balanced regional performance and resumed share buybacks.
-
Full-year organic sales grew 6% with strong EMEA and segment performance, while EBITDA margin improved to 20%. 2025 guidance targets 5%-8% organic growth and 20%-21% EBITDA margin, supported by new product launches and expanded U.S. Medicare coverage.
-
Embla Medical is expanding its global presence and product innovation, with strong growth in bionics and neuro orthotics, and a major boost expected from U.S. Medicare reforms. Financial performance remains robust, with ongoing margin improvements and strategic focus on emerging markets and operational efficiency.
-
Fior & Gentz, now part of a broader growth strategy, is expanding globally with innovative, custom orthotic solutions, leveraging a strong product pipeline and unique configurator tools. The business is highly scalable, maintains strong margins, and is focused on increasing market penetration and education.
-
Strong growth and margin expansion in 2024 were driven by strategic acquisitions, a shift to patient-centric care, and robust performance in key segments. U.S. Medicare's expanded reimbursement for bionics and new product launches set the stage for further growth in 2025.
-
Q3 2024 saw 7% organic sales growth, 22% EBITDA margin, and 58% net profit increase, led by strong EMEA and high-end prosthetics. U.S. Medicare's bionic knee coverage expansion is expected to gradually boost future growth, while APAC growth was mixed and bracing faced price pressure.
-
Medicare's recent coverage expansion is the largest in decades, granting more lower activity amputees access to advanced prosthetics and shifting many to higher functional categories. This creates immediate growth for Medicare patients and a medium to long-term opportunity as commercial payers follow suit.
-
Record Q2 sales and margin expansion driven by prosthetics, neuro-orthotics, and patient care. Guidance for 2024 raised, with new bionic launches and U.S. Medicare changes set to expand the addressable market, though major impacts expected in 2025.